These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8724448)

  • 1. Age-related decline in central cholinergic function demonstrated with scopolamine.
    Tariot PN; Patel SV; Cox C; Henderson RE
    Psychopharmacology (Berl); 1996 May; 125(1):50-6. PubMed ID: 8724448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model.
    Molchan SE; Martinez RA; Hill JL; Weingartner HJ; Thompson K; Vitiello B; Sunderland T
    Brain Res Brain Res Rev; 1992; 17(3):215-26. PubMed ID: 1467811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estradiol treatment and its interaction with the cholinergic system: effects on cognitive function in healthy young women.
    Bartholomeusz CF; Wesnes KA; Kulkarni J; Vitetta L; Croft RJ; Nathan PJ
    Horm Behav; 2008 Nov; 54(5):684-93. PubMed ID: 18706905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed.
    Flicker C; Serby M; Ferris SH
    Psychopharmacology (Berl); 1990; 100(2):243-50. PubMed ID: 2305013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.
    Alvarez-Jimenez R; Groeneveld GJ; van Gerven JM; Goulooze SC; Baakman AC; Hay JL; Stevens J
    Br J Clin Pharmacol; 2016 Oct; 82(4):1011-21. PubMed ID: 27273555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeine attenuates scopolamine-induced memory impairment in humans.
    Riedel W; Hogervorst E; Leboux R; Verhey F; van Praag H; Jolles J
    Psychopharmacology (Berl); 1995 Nov; 122(2):158-68. PubMed ID: 8848531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of acute scopolamine in geriatric depression.
    Newhouse PA; Sunderland T; Tariot PN; Weingartner H; Thompson K; Mellow AM; Cohen RM; Murphy DL
    Arch Gen Psychiatry; 1988 Oct; 45(10):906-12. PubMed ID: 3048225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypersensitivity to scopolamine in the elderly.
    Flicker C; Ferris SH; Serby M
    Psychopharmacology (Berl); 1992; 107(2-3):437-41. PubMed ID: 1615141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scopolamine induced deficits in a battery of rat cognitive tests: comparisons of sensitivity and specificity.
    Hodges DB; Lindner MD; Hogan JB; Jones KM; Markus EJ
    Behav Pharmacol; 2009 May; 20(3):237-51. PubMed ID: 19436198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.
    Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1671-9. PubMed ID: 20142308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.
    Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1681-7. PubMed ID: 19648218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.
    Sunderland T; Tariot PN; Cohen RM; Weingartner H; Mueller EA; Murphy DL
    Arch Gen Psychiatry; 1987 May; 44(5):418-26. PubMed ID: 3579494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man.
    Nuotto E
    Eur J Clin Pharmacol; 1983; 24(5):603-9. PubMed ID: 6873137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central anticholinergic hypersensitivity in aging.
    Ray PG; Meador KJ; Loring DW; Zamrini EW; Yang XH; Buccafusco JJ
    J Geriatr Psychiatry Neurol; 1992; 5(2):72-7. PubMed ID: 1317178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scopolamine challenges in Alzheimer's disease.
    Sunderland T; Tariot P; Murphy DL; Weingartner H; Mueller EA; Cohen RM
    Psychopharmacology (Berl); 1985; 87(2):247-9. PubMed ID: 3931154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aging and cholinergic modulation of the transient magnetic 40-Hz auditory response.
    Ahveninen J; Jääskeläinen IP; Kaakkola S; Tiitinen H; Pekkonen E
    Neuroimage; 2002 Jan; 15(1):153-8. PubMed ID: 11771983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills.
    Duka T; Ott H; Rohloff A; Voet B
    Psychopharmacology (Berl); 1996 Feb; 123(4):361-73. PubMed ID: 8867876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticholinergic challenge and cognitive functions: a comparison between young and elderly normal subjects.
    Zemishlany Z; Thorne AE
    Isr J Psychiatry Relat Sci; 1991; 28(3):32-41. PubMed ID: 1800456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aging, memory, and the cholinergic system: a study of dichotic listening.
    Drachman DA; Noffsinger D; Sahakian BJ; Kurdziel S; Fleming P
    Neurobiol Aging; 1980; 1(1):39-43. PubMed ID: 7266733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of scopolamine on matching to sample paradigm and related tests in human subjects.
    Koller G; Satzger W; Adam M; Wagner M; Kathmann N; Soyka M; Engel R
    Neuropsychobiology; 2003; 48(2):87-94. PubMed ID: 14504417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.